Source comparison
CJC-1295 No DAC Before and After Real Results: Timeline Comparison
Week 1–2 IGF-1 begins rising (10–20% above baseline) Improved sleep depth, slight reduction in DOMS 'Feeling better but no visible change' Too early for composition changes. Baseline establishment period Week 4–6 IGF-1 elevated 50–100% above baseline, sustaine
This comparison does not assign a generated winner or score.
- Week 1–2
- IGF-1 begins rising (10–20% above baseline)
- Improved sleep depth, slight reduction in DOMS
- 'Feeling better but no visible change'
- Too early for composition changes. Baseline establishment period
- Week 4–6
- IGF-1 elevated 50–100% above baseline, sustained GH pulse amplitude
- Modest fat loss in midsection (1–2% body fat), improved muscle fullness during training
- 'Clothes fit slightly better, recovery feels faster'
- First measurable window. Composition changes detectable via DEXA but not always visible
- Week 8–12
- IGF-1 plateau at 1.5–2× baseline, maintained GH elevation
- 2–5% body fat reduction, 1–3kg lean mass gain, enhanced vascularity in conditioned users
- 'Noticeable difference in mirror, strength improvements'
- Peak visual outcome window. Maximal benefit at this stage
- Week 12+
- IGF-1 remains elevated if dosing continues, potential receptor desensitisation without cycling
- Maintenance of composition changes, continued recovery benefits
- 'Sustained improvements but plateau effect'
- Cycling or dose adjustment recommended beyond 12 weeks to avoid diminishing returns
- This table reflects aggregated clinical and observational data. Individual variance is significant. Users with higher baseline body fat (above 20%) see more dramatic fat loss; users already lean (sub-12%) see enhanced muscle detail and vascularity but minimal absolute mass gain.